肺炎克雷伯菌感染与噬菌体疗法

IF 1.4 4区医学 Q4 IMMUNOLOGY

Indian Journal of Medical Microbiology Pub Date : 2024-10-05 DOI:10.1016/j.ijmmb.2024.100736

Alakh Narayan Singh, Aprajita Singh, Sudhir Kumar Singh, Gopal Nath

{"title":"肺炎克雷伯菌感染与噬菌体疗法","authors":"Alakh Narayan Singh, Aprajita Singh, Sudhir Kumar Singh, Gopal Nath","doi":"10.1016/j.ijmmb.2024.100736","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Carbapenem-colistin-resistant <em>Klebsiella pneumoniae</em> has emerged as a serious global problem. <em>Klebsiella pneumoniae</em> is a major culprit in healthcare settings and is responsible for septicemia, urinary tract infections, pneumonia, meningitis, burn wound and surgical site infections, and liver abscesses even in younger and healthier population worldwide. The formation of biofilm prevents antibiotics from reaching the bacteria and exerting their effector mechanism. The non-availability of therapeutic alternatives (antibiotic therapy) further complicates the scenario. However, in the era of antibiotic resistance, bacteriophage therapy emerges as a ray of hope against antibiotic-resistant bacteria.</div></div><div><h3>Method</h3><div>The present review focuses on the therapeutic potential of bacteriophages as an antimicrobial agent with special reference to safety, specificity, efficacy, dosage, and dosage frequency against Pan-Drug Resistant (PDR) <em>K. pneumoniae,</em> both <em>in-vitro</em> and <em>in-vivo</em> (animals and human) studies.</div></div><div><h3>Result</h3><div>This review highlights the perspectives therapeutic potential of bacteriophages, their impact on the host immune system, combination therapy, and bacteriophage-encoded gene product endolysin, artificial lysins (Artilysins), polysaccharide depolymerase, and peptidoglycan hydrolases.</div></div><div><h3>Conclusion</h3><div>This review briefly describes the application of bacteriophage and its encoded gene products in clinical trials.</div></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Klebsiella pneumoniae infections and phage therapy\",\"authors\":\"Alakh Narayan Singh, Aprajita Singh, Sudhir Kumar Singh, Gopal Nath\",\"doi\":\"10.1016/j.ijmmb.2024.100736\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Carbapenem-colistin-resistant <em>Klebsiella pneumoniae</em> has emerged as a serious global problem. <em>Klebsiella pneumoniae</em> is a major culprit in healthcare settings and is responsible for septicemia, urinary tract infections, pneumonia, meningitis, burn wound and surgical site infections, and liver abscesses even in younger and healthier population worldwide. The formation of biofilm prevents antibiotics from reaching the bacteria and exerting their effector mechanism. The non-availability of therapeutic alternatives (antibiotic therapy) further complicates the scenario. However, in the era of antibiotic resistance, bacteriophage therapy emerges as a ray of hope against antibiotic-resistant bacteria.</div></div><div><h3>Method</h3><div>The present review focuses on the therapeutic potential of bacteriophages as an antimicrobial agent with special reference to safety, specificity, efficacy, dosage, and dosage frequency against Pan-Drug Resistant (PDR) <em>K. pneumoniae,</em> both <em>in-vitro</em> and <em>in-vivo</em> (animals and human) studies.</div></div><div><h3>Result</h3><div>This review highlights the perspectives therapeutic potential of bacteriophages, their impact on the host immune system, combination therapy, and bacteriophage-encoded gene product endolysin, artificial lysins (Artilysins), polysaccharide depolymerase, and peptidoglycan hydrolases.</div></div><div><h3>Conclusion</h3><div>This review briefly describes the application of bacteriophage and its encoded gene products in clinical trials.</div></div>\",\"PeriodicalId\":13284,\"journal\":{\"name\":\"Indian Journal of Medical Microbiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Medical Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0255085724002111\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085724002111","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：对碳青霉烯类-科利斯丁耐药的肺炎克雷伯氏菌已成为一个严重的全球性问题。肺炎克雷伯氏菌是医疗机构中的主要罪魁祸首，即使在全球较年轻和健康的人群中，它也是导致脓毒血症、尿路感染、肺炎、脑膜炎、烧伤伤口和手术部位感染以及肝脓肿的罪魁祸首。生物膜的形成阻碍了抗生素进入细菌体内并发挥其作用机制。由于没有替代疗法（抗生素疗法），情况变得更加复杂。然而，在抗生素耐药性时代，噬菌体疗法的出现为抗击耐抗生素细菌带来了一线希望：方法：本综述侧重于噬菌体作为抗菌剂的治疗潜力，特别是在体外和体内（动物和人体）研究中，针对泛耐药（PDR）肺炎克氏菌的安全性、特异性、疗效、剂量和用药频率：本综述重点介绍了噬菌体的治疗潜力、噬菌体对宿主免疫系统的影响、联合疗法以及噬菌体编码的基因产物内溶菌酶、人工溶菌酶（Artilysins）、多糖解聚酶和肽聚糖水解酶：本综述简要介绍了噬菌体及其编码基因产品在临床试验中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Klebsiella pneumoniae infections and phage therapy

Objective

Carbapenem-colistin-resistant Klebsiella pneumoniae has emerged as a serious global problem. Klebsiella pneumoniae is a major culprit in healthcare settings and is responsible for septicemia, urinary tract infections, pneumonia, meningitis, burn wound and surgical site infections, and liver abscesses even in younger and healthier population worldwide. The formation of biofilm prevents antibiotics from reaching the bacteria and exerting their effector mechanism. The non-availability of therapeutic alternatives (antibiotic therapy) further complicates the scenario. However, in the era of antibiotic resistance, bacteriophage therapy emerges as a ray of hope against antibiotic-resistant bacteria.

Method

The present review focuses on the therapeutic potential of bacteriophages as an antimicrobial agent with special reference to safety, specificity, efficacy, dosage, and dosage frequency against Pan-Drug Resistant (PDR) K. pneumoniae, both in-vitro and in-vivo (animals and human) studies.

Result

This review highlights the perspectives therapeutic potential of bacteriophages, their impact on the host immune system, combination therapy, and bacteriophage-encoded gene product endolysin, artificial lysins (Artilysins), polysaccharide depolymerase, and peptidoglycan hydrolases.

Conclusion

This review briefly describes the application of bacteriophage and its encoded gene products in clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.